Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.

Cell cycle (Georgetown, Tex.) - 1 Sept 2016

Marullo Rossella, Rutherford Sarah C, Leonard John P, Cerchietti Leandro

Abstract excerpt

A subset of diffuse large B-cell lymphomas (DLBCL) harbors concomitant rearrangements of MYC, BCL2 and BCL6 and is characterized by clinical aggressiveness and intrinsic refractoriness to standard chemo-immunotherapy. Commonly identified as "double or triple hit" lymphomas, these diseases represent a therapeutic challenge to chemotherapy-based regimens and likely require a more targeted approach. Herein we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Aberrations
Share to BCL2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCL6 gene

Share to Lymphoma, B-Cell

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasm Invasiveness

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 27419806
DOI: 10.1080/15384101.2016.1207839
PMCID: PMC5004704

Genes

BCL2
BCL6
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.PMID 27419806Read ↗

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approachesSemantic proximity Read ↗

Double hit lymphoma: from biology to therapeutic implications.Semantic proximity Read ↗

Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Semantic proximity Read ↗

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.Semantic proximity Read ↗

Emerging Strategies in Treating Double Hit Lymphomas.Semantic proximity Read ↗

The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Double-hit B-cell lymphomasSemantic proximity Read ↗

Biology of double-hit B-cell lymphomasSemantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.